Sarepta Therapeutics (NASDAQ:SRPT) Sees Large Volume Increase - Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares saw strong trading volume on Tuesday . 2,418,407 shares were traded during trading, a decline of 18% from the previous session's volume of 2,952,478 shares.The stock last traded at $22.69 and had previously closed at $20.94.

Analysts Set New Price Targets

A number of brokerages have commented on SRPT. Barclays reduced their target price on Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a report on Tuesday. Robert W. Baird decreased their target price on Sarepta Therapeutics from $60.00 to $30.00 and set an "outperform" rating on the stock in a research note on Tuesday. Mizuho decreased their price objective on Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating for the company in a research note on Wednesday. Oppenheimer dropped their price target on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, HC Wainwright cut shares of Sarepta Therapeutics from a "neutral" rating to a "sell" rating in a report on Monday. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Hold" and a consensus price target of $67.64.

Sarepta Therapeutics Stock Performance

The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $1.97 billion, a PE ratio of -7.46 and a beta of 0.61. The stock's 50 day moving average price is $43.71 and its two-hundred day moving average price is $83.62.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 EPS. On average, equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at approximately $30,000. Center for Financial Planning Inc. bought a new position in Sarepta Therapeutics in the 1st quarter valued at about $31,000. Ancora Advisors LLC raised its stake in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after buying an additional 300 shares in the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after buying an additional 194 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in Sarepta Therapeutics during the first quarter valued at about $44,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.